Company intelligence / Profile preview

Sutura Therapeutics

Macclesfield, England, United Kingdomsutura.com ↗

Ownership: Private
Development stage: Other

Overview

Sutura Therapeutics developed a proprietary peptide-based platform ("PeptiGo") to create next-generation biomolecular medicines targeting indications that are not addressable by conventional small molecules. Their lead program reached preclinical/early clinical stage for Duchenne Muscular Dystrophy. The company entered liquidation in the UK as of early 2025 and is no longer active.

Therapeutic areas: Rare DiseasesNeurologyInfectious Diseases
Modalities: Peptide-based drug conjugatesCell Penetrating Peptides (CPPs)Antisense oligonucleotides (ASO)
Industry: Biotech

Partnerships

No major pharmaceutical or biotech partnerships publicly reported

Beyond the preview

Go deeper on Sutura Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Sutura Therapeutics.

Explore the full profile